Brief: Celldex Therapeutics Presents Data Demonstrating Profound Improvements In Angioedema In Barzolvolimab Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci 2024
02/06/2024 14:03
June 2 (Reuters) - Celldex Therapeutics Inc CLDX.O :
* CELLDEX THERAPEUTICS PRESENTS DATA DEMONSTRATING PROFOUND
IMPROVEMENTS IN ANGIOEDEMA IN BARZOLVOLIMAB PHASE 2 STUDY IN
CHRONIC SPONTANEOUS URTICARIA AT EAACI 2024
* CELLDEX THERAPEUTICS INC - DATA FURTHER SUPPORT
BARZOLVOLIMAB
CLINICAL BENEFIT TO PATIENTS WITH CSU
Source text for Eikon: ID:nGNX4xwZj8
Further company coverage: CLDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celldex Therapeutics
See all newsUS RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Celldex shares slip as safety concerns cloud skin drug trial win (updated)
Celldex falls after two probable anaphylaxis cases in trials
Celldex's skin disease drug meets goals in two late-stage trials